Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
Executive Summary
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.
You may also be interested in...
Bumpy EU Review Ends Well For Selinexor Filing
Karyopharm says its treatment for patients with refractory multiple myeloma could become its first product to be approved in Europe.
EU Crunch Time For Two Drugs That Lost Their Fast-Track Status
Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.
Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: